

Tapinarof Cream 1%: Adis Evaluation

Key Points

- An AhR agonist that is being developed by Dermavant Sciences Inc. (a subsidiary of Roivant Sciences Inc.) as a topical treatment for plaque psoriasis and atopic dermatitis
- Received its first approval on 23 May 2022 in the USA
- Approved for the topical treatment of plaque psoriasis in adults

Summary

Tapinarof cream 1% (VTAMA®) is an aryl hydrocarbon receptor (AhR) agonist that is being developed by Dermavant Sciences Inc. (a subsidiary of Roivant Sciences Inc.) as a once-daily topical treatment for plaque psoriasis and atopic dermatitis.

AhR is a ligand-dependent transcription factor that has a role in immune-mediated skin responses.

In May 2022, tapinarof cream 1% was approved in the USA for the topical treatment of plaque psoriasis in adults. Tapinarof cream 1% is also being investigated for the treatment of atopic dermatitis.

This summary represents the opinions of the [author/authors]. For a full list of declarations, including funding and author disclosure statements, please see the full text online. © Springer Nature Switzerland AG 2022.